GlaxoSmithKline Pharmaceuticals (GSK Pharma) is undertaking measures to increase sustainability in its plant operations. The company will procure 4.95 MWp of solar power for its plant at Nashik, Maharashtra, from Clean Max Enviro Energy Solutions (CleanMax) under the group captive mechanism.

The company’s Board of Directors approved an investment of INR 1.74 crore for the solar power project, the company said in a regulatory filing.

GSK Pharma will acquire 26 percent stake in CleanMax’s special purpose vehicle (SPV) Clean Max Galapagos at INR 173.61 lakh. The acquisition will be completed within 180 days.

The company, in its Business Responsibility and Sustainability Report for FY24, has mentioned that it has undertaken active projects related to reducing greenhouse gas emissions. “These include a 1 MWp solar power plant that has the potential to provide 15 percent of the electricity requirement and a 5.1 MWp solar plant, leading to a potential carbon reduction of 163 MT,” it mentioned.

In FY25, the company has consumed 52,543 GJ of energy from renewable sourcing which is about 48.64 percent of total energy consumed. In FY25, the company also installed a 330 kWp solar power plant.

Globally, to achieve its goal of having a net-zero impact on climate, GSK has set a series of ambitious targets measured against a 2020 baseline. The company aims to reduce absolute greenhouse gas emissions by 80 percent across all scopes by 2030, while investing in nature-based solutions to offset the remaining 20 percent of its footprint.

GSK is targeting 100 percent imported renewable electricity by 2025 and 100 percent renewable electricity – both imported and self-generated – by 2030 for its Scope 2 emissions. By 2045, the company plans to achieve net-zero greenhouse gas emissions across its entire value chain, with a 90 percent absolute reduction from the 2020 baseline and full neutralisation of all residual emissions.